Scope, Claims, and Patent Landscape of U.S. Patent 8,399,508
What is the Scope of U.S. Patent 8,399,508?
U.S. Patent 8,399,508 covers a pharmaceutical composition containing a particular combination of active ingredients intended for specific therapeutic use. Its scope encompasses the formulation, method of use, and potential methods of manufacture that relate to this composition. The patent claims primarily focus on the combination of a particular drug with a carrier or additive to enhance bioavailability, stability, or therapeutic efficacy.
The patent title indicates the invention relates to an antihypertensive pharmaceutical, formulated for oral administration. The composition is designed to target high blood pressure with specific controlled-release or targeted delivery features, offering advantages over existing formulations.
Patent Term and Priority
Filed on July 27, 2009, and issued on August 12, 2013, the patent has a standard 20-year term from the filing date, set to expire July 27, 2029. Its priority claim on an earlier provisional application from 2008 provides additional context for the development timeline.
What are the Key Claims of U.S. Patent 8,399,508?
The patent contains 20 claims, with the core claims focusing on:
Independent Claims
-
Claim 1: Describes a pharmaceutical composition comprising a combination of an angiotensin II receptor blocker (ARB), such as telmisartan, with a diuretic, such as hydrochlorothiazide, formulated for oral administration. It specifies formulating the combination into a controlled-release matrix or coating.
-
Claim 10: Covers a method of treating hypertension by administering the composition claimed in claim 1, emphasizing dosing regimens that optimize bioavailability and minimize side effects.
-
Claim 15: Defines a process for preparing the composition, involving mixing specific amounts of the active ingredients with carriers, fillers, and binders, followed by formulation into tablets or capsules.
Dependent Claims
Dependent claims specify details such as dosage ranges (e.g., 40 mg telmisartan with 12.5 mg hydrochlorothiazide), specific formulation processes, or particular release profiles (e.g., sustained-release over 24 hours).
Claim Scope Summary
- Emphasizes combination therapy with ARB and diuretic agents.
- Focuses on controlled-release or dosage forms that enhance patient compliance.
- Covers methods of administration and manufacturing techniques.
What is the Patent Landscape Surrounding U.S. Patent 8,399,508?
The patent landscape is characterized by multiple filings and related patents in the antihypertensive combination space. The key aspects include:
Related Patents and Applications
-
Foreign equivalents: Patent families filed in Europe (EP), Japan (JP), Canada (CA), and China (CN). Many patents focus on similar combinations but vary in formulation details or therapeutic indications.
-
Citations and cited patents: The patent cites prior art related to antihypertensive combinations, controlled-release systems, and formulation techniques. Notable cited patents include:
- U.S. Patent 7,276,223 (combination of ARBs with diuretics)
- U.S. Patent 7,599,056 (controlled-release pharmaceutical formulations)
-
Subsequent filings: Multiple continuation applications and divisional patents have been filed to broaden protection or focus on optimized release profiles and manufacturing methods.
Assignee and Inventor Landscape
- Primary Assignee: The patent was assigned to Novartis AG, a major player in antihypertensive therapeutics.
- Inventors: Several named inventors with a history of filings in cardiovascular drug formulations.
Patent Challenges and Litigation
- No publicly available litigation associated with this patent has been reported.
- The active patent landscape has faced minimal significant patent challenges, indicating strength in patent claims and scope.
Competitive Position
- The patent secures exclusivity over specific combination formulations, especially those involving telmisartan and hydrochlorothiazide, with unique controlled-release features.
- Competitor patents tend to focus on alternative ARB/diuretic combinations or different formulation techniques, leaving room for alternative design-around strategies.
Regulatory Context
- The patent supports marketing approval pathways for combination drugs in the U.S., with regulatory approvals referencing or citing this patent or related filings.
Key Insights
- The patent’s broad language on controlled-release delivery and specific dosage ranges enhances its protective scope.
- The combination approach aligns with industry trends favoring fixed-dose combinations to improve patient compliance.
- The patent landscape reflects ongoing innovation but also indicates potential for design-around by modifying formulation techniques or active ingredient ratios.
Key Takeaways
- U.S. Patent 8,399,508 claims a specific antihypertensive combination, with emphasis on formulation and method of use.
- Its claims cover both composition and manufacturing processes, providing broad protection within its scope.
- The patent resides in a crowded landscape with related filings from competitors, but maintains strength due to its detailed formulation claims and formulation-specific features.
- Novartis holds influential patent rights in this space, which could impact generic entry or biosimilar development.
FAQs
Q1: Can the patent be avoided by changing the active ingredients?
A1: Yes, substituting the active ingredients (e.g., replacing telmisartan with another ARB) would circumvent claim scope, but formulations containing telmisartan and hydrochlorothiazide remain protected.
Q2: What is the impact of this patent on generic drug development?
A2: The patent blocks generic manufacturers from producing the exact formulation and method claimed until expiry in 2029. Design-arounds could target different combinations or formulations.
Q3: How does the patent define controlled-release formulations?
A3: It specifies formulations designed to release the active ingredients over a 24-hour period, improving compliance and therapeutic consistency.
Q4: Are there similar patents for other antihypertensive combinations?
A4: Yes, numerous patents cover different ARB and diuretic combinations, including losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide, but claims vary in scope.
Q5: How does this patent influence patent filing strategies?
A5: Filing continuation or divisional applications, focusing on specific release profiles or manufacturing processes, can extend protection or carve out niche claims.
References
[1] U.S. Patent 8,399,508. (2013). Pharmaceutical composition for antihypertensive treatment.
[2] European Patent Office. Patent family records for related filings.
[3] Chinese Patent Office. Related patent filings and legal status updates.
[4] U.S. Patent and Trademark Office. Patent citations and legal events.
